← back to search

Weiyi Peng

Center for Cancer Research · US
Area of research
Oncology · Molecular Biology
Research interest
Research interests include Cancer research, Immunotherapy, Tumor microenvironment, Melanoma, Immune system, and Immune checkpoint.
h-index
citations
3,717
works
15
NIH funding
primary concept
email

Recent publications

Tumor Intrinsic METTL5 Modulates ATF4 Translation to Prevent T Cell‐Induced Ferroptosis in Ovarian Cancer
Advanced Science 2025cited by 2position: lastdoi
Development of a RIPK1 degrader to enhance antitumor immunity
Nature Communications 2024cited by 25position: middledoi
Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
Clinical Cancer Research 2022cited by 34position: middledoi
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
Nature Communications 2021cited by 216position: middledoi
The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies
Molecular Cancer Therapeutics 2020cited by 159position: middledoi
Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer
Nature Communications 2019cited by 263position: middledoi
A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma
Clinical Cancer Research 2019cited by 94position: middledoi
Abstract 4152: Irreversible electroporation induces immunogenic cell death and mediates durable response in orthotopic PDAC model in combination with anti-PD-1
Cancer Research 2019cited by 1position: middledoi
Abstract 4152: Irreversible electroporation induces immunogenic cell death and mediates durable response in orthotopic PDAC model in combination with anti-PD-1
Clinical Research (Excluding Clinical Trials) 2019cited by 1position: middledoi
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy
Cell Metabolism 2018cited by 620position: lastdoi
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Cancer Discovery 2018cited by 466position: middledoi
The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression
Clinical Cancer Research 2018cited by 97position: middledoi
Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications
Pigment Cell & Melanoma Research 2017cited by 195position: middledoi
Melanoma and immunotherapy bridge 2015
Journal of Translational Medicine 2016cited by 24position: middledoi
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Cancer Discovery 2015cited by 1,520position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Jennifer L. McQuade · The University of Texas MD Anderson Cancer Center3 papers (2017–2020)Grant M. Fischer · The University of Texas Health Science Center at Houston3 papers (2017–2020) · 3 papers (2017–2020)Chun Li · Tianjin University3 papers (2019–2019)Xiaofei Wen · Shanghai Medical College of Fudan University3 papers (2019–2019)Marites P. Melancon · University of Houston3 papers (2019–2019) · 2 papers (2019–2020) · 2 papers (2019–2020)Sanjay Gupta · The University of Texas MD Anderson Cancer Center2 papers (2019–2019)Courtney W. Hudgens · The University of Texas MD Anderson Cancer Center2 papers (2019–2020)Ralph J. DeBerardinis · Children's Medical Center2 papers (2017–2019)Jun Zhao · Changzhi Medical College2 papers (2019–2019)Jason Roszik · The University of Texas MD Anderson Cancer Center2 papers (2019–2020)Michael A. Davies · IT University of Copenhagen2 papers (2017–2019)Ningping Feng · The University of Texas MD Anderson Cancer Center1 papers (2019–2019)Bryan L. Holloman · University of South Carolina1 papers (2024–2024)Jin Wang · Henan Medical University1 papers (2024–2024)Xin Yu · National Institutes of Health1 papers (2024–2024)Andrew L. MacKinnon · Calithera (United States)1 papers (2020–2020)Dong Lu · Baylor College of Medicine1 papers (2024–2024)